BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. (BCT.TO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · BCT.TO · as of Jun 8, 2026
Key Statistics
Explore BriaCell Therapeutics Corp. Data
bct.to stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 1 · Buy rate: 100.0%
Competitors & Peers
bct.to competitorsBCT.TO
DOSE.CN
GLAB.CN
GWAY.CN
HEM.V
IZO.CNStock Performance
Full HistoryAbout BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp. an immuno-oncology-focused biotechnology company, engages in developing immunotherapies for the management of cancer. Its lead drug candidate is Bria-IMT, a whole-cell can…
what is briacell therapeutics corp. · bct.to stock overview · briacell therapeutics corp. company profile · who is briacell therapeutics corp. ceo · bct.to TSX · briacell therapeutics corp. headquarters · briacell therapeutics corp. business segments
About Stock Overview & Key Data
BriaCell Therapeutics Corp. (BCT.TO) is a Healthcare company in the Biotechnology industry, listed on TSX since Aug 13, 2012. As of the latest trading session, BCT.TO stock price is $4.31, with a market capitalization of $8.1M. The stock has returned -90.96% over the past 12 months and -56.02% year-to-date.
According to 1 Wall Street analysts, the consensus rating for BriaCell Therapeutics Corp. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, BriaCell Therapeutics Corp. reported revenue of — and net income of -$26.6M. For detailed data — including BriaCell Therapeutics Corp. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, BriaCell Therapeutics Corp. (BCT.TO) stock price is $4.31. The stock is traded on TSX under the ticker symbol BCT.TO. The 52-week range is $4.13 – $49.00.